AZB, Khaitan, CAM, Veritas on Everstone's purchase of 70% stake in Rubicon for 220 crore

Bar & Bench January 9 2017

Everstone Capital Asia has acquired a 70% controlling stake in Mumbai-based tech drug firm Rubicon Research for Rs. 220 crore.

The deal involved a primary and secondary acquisition of shares of Rubicon. The secondary acquisition involved a purchase of shares by Everstone from two Kotak domestic entities, Kotak Employees Investment Trust (KEIT) and Kotak India Venture Fund I (KIVF) and one offshore entity Kotak India Venture (Offshore) Fund (KIVOF).

Everstone acquires 70% stake in Rubicon

220 crore

Deal Type

You need to have an active subscription to view this content.